ARTICLE | Clinical News
Ispinesib: Phase II started
August 1, 2005 7:00 AM UTC
CYTK started an open-label, monotherapy, U.S. Phase II trial in 40 patients to evaluate ispinesib as a second-line treatment in patients with hormone-refractory prostate cancer. ...